Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis.

The Journal of international medical research

Ganzetti G, Campanati A, Santarelli A, Sartini D, Molinelli E, Brisigotti V, Di Ruscio G, Bobyr I, Emanuelli M, Offidani A.
PMID: 27683132
J Int Med Res. 2016 Sep;44(1):10-14. doi: 10.1177/0300060515598902.

OBJECTIVE: To evaluate salivary interleukin (IL)-1β levels in patients with psoriasis, before and after treatment with tumour necrosis factor (TNF)-α inhibitors.METHODS: In this pilot study, salivary secretions were collected from patients with psoriasis and untreated healthy control subjects at...

Cite
Ganzetti G, Campanati A, Santarelli A, et al. Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis. J Int Med Res. 2016;44(1):10-14doi: 10.1177/0300060515598902.
Ganzetti, G., Campanati, A., Santarelli, A., Sartini, D., Molinelli, E., Brisigotti, V., Di Ruscio, G., Bobyr, I., Emanuelli, M., & Offidani, A. (2016). Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis. The Journal of international medical research, 44(1), 10-14. https://doi.org/10.1177/0300060515598902
Ganzetti, Giulia, et al. "Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis." The Journal of international medical research vol. 44,1 (2016): 10-14. doi: https://doi.org/10.1177/0300060515598902
Ganzetti G, Campanati A, Santarelli A, Sartini D, Molinelli E, Brisigotti V, Di Ruscio G, Bobyr I, Emanuelli M, Offidani A. Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis. J Int Med Res. 2016 Sep;44(1):10-14. doi: 10.1177/0300060515598902. PMID: 27683132; PMCID: PMC5536539.
Copy Download .nbib Format: NLM
Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines.

Pigment cell & melanoma research

Campagna R, Salvolini E, Pompei V, Pozzi V, Salvucci A, Molinelli E, Brisigotti V, Sartini D, Campanati A, Offidani A, Emanuelli M.
PMID: 34018676
Pigment Cell Melanoma Res. 2021 Nov;34(6):1039-1048. doi: 10.1111/pcmr.12993. Epub 2021 May 28.

Melanoma accounts for less than 5% of all cutaneous neoplasms but is responsible for the greater part of skin cancer-related deaths. Therefore, the identification of molecules that could serve as the therapeutic target is urgent. This study focused on...

Cite
Campagna R, Salvolini E, Pompei V, et al. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell Melanoma Res. 2021;34(6):1039-1048doi: 10.1111/pcmr.12993.
Campagna, R., Salvolini, E., Pompei, V., Pozzi, V., Salvucci, A., Molinelli, E., Brisigotti, V., Sartini, D., Campanati, A., Offidani, A., & Emanuelli, M. (2021). Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment cell & melanoma research, 34(6), 1039-1048. https://doi.org/10.1111/pcmr.12993
Campagna, Roberto, et al. "Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines." Pigment cell & melanoma research vol. 34,6 (2021): 1039-1048. doi: https://doi.org/10.1111/pcmr.12993
Campagna R, Salvolini E, Pompei V, Pozzi V, Salvucci A, Molinelli E, Brisigotti V, Sartini D, Campanati A, Offidani A, Emanuelli M. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell Melanoma Res. 2021 Nov;34(6):1039-1048. doi: 10.1111/pcmr.12993. Epub 2021 May 28. PMID: 34018676.
Copy Download .nbib Format: NLM
Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma.

Human cell

Sartini D, Campagna R, Lucarini G, Pompei V, Salvolini E, Mattioli-Belmonte M, Molinelli E, Brisigotti V, Campanati A, Bacchetti T, Ferretti G, Offidani A, Emanuelli M.
PMID: 34302630
Hum Cell. 2021 Nov;34(6):1929-1931. doi: 10.1007/s13577-021-00581-5. Epub 2021 Jul 24.

No abstract available.

Cite
Sartini D, Campagna R, Lucarini G, et al. Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. Hum Cell. 2021;34(6):1929-1931doi: 10.1007/s13577-021-00581-5.
Sartini, D., Campagna, R., Lucarini, G., Pompei, V., Salvolini, E., Mattioli-Belmonte, M., Molinelli, E., Brisigotti, V., Campanati, A., Bacchetti, T., Ferretti, G., Offidani, A., & Emanuelli, M. (2021). Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. Human cell, 34(6), 1929-1931. https://doi.org/10.1007/s13577-021-00581-5
Sartini, Davide, et al. "Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma." Human cell vol. 34,6 (2021): 1929-1931. doi: https://doi.org/10.1007/s13577-021-00581-5
Sartini D, Campagna R, Lucarini G, Pompei V, Salvolini E, Mattioli-Belmonte M, Molinelli E, Brisigotti V, Campanati A, Bacchetti T, Ferretti G, Offidani A, Emanuelli M. Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. Hum Cell. 2021 Nov;34(6):1929-1931. doi: 10.1007/s13577-021-00581-5. Epub 2021 Jul 24. PMID: 34302630.
Copy Download .nbib Format: NLM
Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study.

Journal of the American Academy of Dermatology

Molinelli E, Sapigni C, Simonetti O, Brisigotti V, Giuliodori K, Offidani A.
PMID: 34774922
J Am Acad Dermatol. 2021 Nov 11; doi: 10.1016/j.jaad.2021.10.060. Epub 2021 Nov 11.

No abstract available.

Cite
Molinelli E, Sapigni C, Simonetti O, et al. Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study. J Am Acad Dermatol. 2021;doi: 10.1016/j.jaad.2021.10.060.
Molinelli, E., Sapigni, C., Simonetti, O., Brisigotti, V., Giuliodori, K., & Offidani, A. (2021). Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study. Journal of the American Academy of Dermatology, . https://doi.org/10.1016/j.jaad.2021.10.060
Molinelli, Elisa, et al. "Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study." Journal of the American Academy of Dermatology vol. (2021). doi: https://doi.org/10.1016/j.jaad.2021.10.060
Molinelli E, Sapigni C, Simonetti O, Brisigotti V, Giuliodori K, Offidani A. Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study. J Am Acad Dermatol. 2021 Nov 11; doi: 10.1016/j.jaad.2021.10.060. Epub 2021 Nov 11. PMID: 34774922.
Copy Download .nbib Format: NLM
Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study.

European journal of dermatology : EJD

Campanati A, Diotallevi F, Radi G, Molinelli E, Brisigotti V, Martina E, Paolinelli M, Bianchelli T, Covi C, Bartezaghi M, Offidani A.
PMID: 34789441
Eur J Dermatol. 2021 Oct 01;31(5):630-637. doi: 10.1684/ejd.2021.4150.

BACKGROUND: Achieving minimal disease activity (MDA) represents an ambitious and sustainable therapeutic goal in psoriasis. Clear criteria for defining MDA in psoriasis are lacking.OBJECTIVES: The primary outcome was to evaluate the effect of 300 mg secukinumab in achieving MDA...

Cite
Campanati A, Diotallevi F, Radi G, et al. Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. Eur J Dermatol. 2021;31(5):630-637doi: 10.1684/ejd.2021.4150.
Campanati, A., Diotallevi, F., Radi, G., Molinelli, E., Brisigotti, V., Martina, E., Paolinelli, M., Bianchelli, T., Covi, C., Bartezaghi, M., & Offidani, A. (2021). Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. European journal of dermatology : EJD, 31(5), 630-637. https://doi.org/10.1684/ejd.2021.4150
Campanati, Anna, et al. "Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study." European journal of dermatology : EJD vol. 31,5 (2021): 630-637. doi: https://doi.org/10.1684/ejd.2021.4150
Campanati A, Diotallevi F, Radi G, Molinelli E, Brisigotti V, Martina E, Paolinelli M, Bianchelli T, Covi C, Bartezaghi M, Offidani A. Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. Eur J Dermatol. 2021 Oct 01;31(5):630-637. doi: 10.1684/ejd.2021.4150. PMID: 34789441.
Copy Download .nbib Format: NLM
Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study.

Dermatology and therapy

Molinelli E, Campanati A, Brisigotti V, Sapigni C, Paolinelli M, Offidani A.
PMID: 32342443
Dermatol Ther (Heidelb). 2020 Jun;10(3):515-521. doi: 10.1007/s13555-020-00379-7. Epub 2020 Apr 27.

INTRODUCTION: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent...

Cite
Molinelli E, Campanati A, Brisigotti V, et al. Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study. Dermatol Ther (Heidelb). 2020;10(3):515-521doi: 10.1007/s13555-020-00379-7.
Molinelli, E., Campanati, A., Brisigotti, V., Sapigni, C., Paolinelli, M., & Offidani, A. (2020). Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study. Dermatology and therapy, 10(3), 515-521. https://doi.org/10.1007/s13555-020-00379-7
Molinelli, Elisa, et al. "Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study." Dermatology and therapy vol. 10,3 (2020): 515-521. doi: https://doi.org/10.1007/s13555-020-00379-7
Molinelli E, Campanati A, Brisigotti V, Sapigni C, Paolinelli M, Offidani A. Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study. Dermatol Ther (Heidelb). 2020 Jun;10(3):515-521. doi: 10.1007/s13555-020-00379-7. Epub 2020 Apr 27. PMID: 32342443; PMCID: PMC7211771.
Copy Download .nbib Format: NLM
Alexandrite laser as an adjuvant therapy in the management of mild-moderate hidradenitis suppurativa: a controlled prospective clinical study.

Journal of the American Academy of Dermatology

Molinelli E, Sapigni C, Simonetti O, Brisigotti V, Giuliodori K, Offidani A.
PMID: 34774922
J Am Acad Dermatol. 2021 Nov 11; doi: 10.1016/j.jaad.2021.10.060. Epub 2021 Nov 11.

No abstract available.

Cite
Molinelli E, Sapigni C, Simonetti O, et al. Alexandrite laser as an adjuvant therapy in the management of mild-moderate hidradenitis suppurativa: a controlled prospective clinical study. J Am Acad Dermatol. 2021;doi: 10.1016/j.jaad.2021.10.060.
Molinelli, E., Sapigni, C., Simonetti, O., Brisigotti, V., Giuliodori, K., & Offidani, A. (2021). Alexandrite laser as an adjuvant therapy in the management of mild-moderate hidradenitis suppurativa: a controlled prospective clinical study. Journal of the American Academy of Dermatology, . https://doi.org/10.1016/j.jaad.2021.10.060
Molinelli, E, et al. "Alexandrite laser as an adjuvant therapy in the management of mild-moderate hidradenitis suppurativa: a controlled prospective clinical study." Journal of the American Academy of Dermatology vol. (2021). doi: https://doi.org/10.1016/j.jaad.2021.10.060
Molinelli E, Sapigni C, Simonetti O, Brisigotti V, Giuliodori K, Offidani A. Alexandrite laser as an adjuvant therapy in the management of mild-moderate hidradenitis suppurativa: a controlled prospective clinical study. J Am Acad Dermatol. 2021 Nov 11; doi: 10.1016/j.jaad.2021.10.060. Epub 2021 Nov 11. PMID: 34774922.
Copy Download .nbib Format: NLM
Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma.

Dermatopathology (Basel, Switzerland)

Simonetti O, Molinelli E, Brisigotti V, Brancorsini D, Talevi D, Offidani A.
PMID: 33535371
Dermatopathology (Basel). 2021 Feb 01;8(1):29-32. doi: 10.3390/dermatopathology8010005.

Primary dermal melanoma (PDM) is a rare distinct variant of cutaneous melanoma, predominantly occurring on the extremities of young or middle-aged adults. In comparison to conventional melanoma, PDM is characterized by unexpectedly prolonged survival and long-term survival. Thus, correct...

Cite
Simonetti O, Molinelli E, Brisigotti V, et al. Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma. Dermatopathology (Basel). 2021;8(1):29-32doi: 10.3390/dermatopathology8010005.
Simonetti, O., Molinelli, E., Brisigotti, V., Brancorsini, D., Talevi, D., & Offidani, A. (2021). Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma. Dermatopathology (Basel, Switzerland), 8(1), 29-32. https://doi.org/10.3390/dermatopathology8010005
Simonetti, Oriana, et al. "Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma." Dermatopathology (Basel, Switzerland) vol. 8,1 (2021): 29-32. doi: https://doi.org/10.3390/dermatopathology8010005
Simonetti O, Molinelli E, Brisigotti V, Brancorsini D, Talevi D, Offidani A. Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma. Dermatopathology (Basel). 2021 Feb 01;8(1):29-32. doi: 10.3390/dermatopathology8010005. PMID: 33535371; PMCID: PMC7931035.
Copy Download .nbib Format: NLM
Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study.

European journal of dermatology : EJD

Campanati A, Diotallevi F, Radi G, Molinelli E, Brisigotti V, Martina E, Paolinelli M, Bianchelli T, Covi C, Bartezaghi M, Offidani A.
PMID: 34789441
Eur J Dermatol. 2021 Oct 01;31(5):630-637. doi: 10.1684/ejd.2021.4150.

BACKGROUND: Achieving minimal disease activity (MDA) represents an ambitious and sustainable therapeutic goal in psoriasis. Clear criteria for defining MDA in psoriasis are lacking.OBJECTIVES: The primary outcome was to evaluate the effect of 300 mg secukinumab in achieving MDA...

Cite
Campanati A, Diotallevi F, Radi G, et al. Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. Eur J Dermatol. 2021;31(5):630-637doi: 10.1684/ejd.2021.4150.
Campanati, A., Diotallevi, F., Radi, G., Molinelli, E., Brisigotti, V., Martina, E., Paolinelli, M., Bianchelli, T., Covi, C., Bartezaghi, M., & Offidani, A. (2021). Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. European journal of dermatology : EJD, 31(5), 630-637. https://doi.org/10.1684/ejd.2021.4150
Campanati, Anna, et al. "Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study." European journal of dermatology : EJD vol. 31,5 (2021): 630-637. doi: https://doi.org/10.1684/ejd.2021.4150
Campanati A, Diotallevi F, Radi G, Molinelli E, Brisigotti V, Martina E, Paolinelli M, Bianchelli T, Covi C, Bartezaghi M, Offidani A. Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. Eur J Dermatol. 2021 Oct 01;31(5):630-637. doi: 10.1684/ejd.2021.4150. PMID: 34789441.
Copy Download .nbib Format: NLM
Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report.

Journal of medical case reports

Nicoletti S, Papi M, Drudi F, Fantini M, Canuti D, Tamburini E, Possenti C, Pasquini E, Brisigotti M, Ravaioli A.
PMID: 20591162
J Med Case Rep. 2010 Jun 30;4:201. doi: 10.1186/1752-1947-4-201.

INTRODUCTION: Small cell neuroendocrine cancer of the breast is a rare tumor with less than 30 cases reported in the literature. The morphological and immunohistochemical patterns of this tumor are similar to small cell neuroendocrine cancer of the lung....

Cite
Nicoletti S, Papi M, Drudi F, et al. Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report. J Med Case Rep. 2010;4:201doi: 10.1186/1752-1947-4-201.
Nicoletti, S., Papi, M., Drudi, F., Fantini, M., Canuti, D., Tamburini, E., Possenti, C., Pasquini, E., Brisigotti, M., & Ravaioli, A. (2010). Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report. Journal of medical case reports, 4201. https://doi.org/10.1186/1752-1947-4-201
Nicoletti, Stefania, et al. "Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report." Journal of medical case reports vol. 4 (2010): 201. doi: https://doi.org/10.1186/1752-1947-4-201
Nicoletti S, Papi M, Drudi F, Fantini M, Canuti D, Tamburini E, Possenti C, Pasquini E, Brisigotti M, Ravaioli A. Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report. J Med Case Rep. 2010 Jun 30;4:201. doi: 10.1186/1752-1947-4-201. PMID: 20591162; PMCID: PMC2913980.
Copy Download .nbib Format: NLM
Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption.

Case reports in dermatology

Campanati A, Molinelli E, Brisigotti V, Brancorsini D, Bobyr I, Diotallevi F, Radi G, Offidani A.
PMID: 31662732
Case Rep Dermatol. 2019 Sep 23;11:4-10. doi: 10.1159/000501992. eCollection 2019.

Kaposi's varicelliform eruption (KVE) is a disseminated cutaneous infection usually induced by herpesvirus type 1 or 2, vaccinia virus or Coxsackie A16 virus in a patient with an underlying dermatosis. Risk factors for KVE reported in the literature include...

Cite
Campanati A, Molinelli E, Brisigotti V, et al. Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption. Case Rep Dermatol. 2019;11:4-10doi: 10.1159/000501992.
Campanati, A., Molinelli, E., Brisigotti, V., Brancorsini, D., Bobyr, I., Diotallevi, F., Radi, G., & Offidani, A. (2019). Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption. Case reports in dermatology, 114-10. https://doi.org/10.1159/000501992
Campanati, Anna, et al. "Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption." Case reports in dermatology vol. 11 (2019): 4-10. doi: https://doi.org/10.1159/000501992
Campanati A, Molinelli E, Brisigotti V, Brancorsini D, Bobyr I, Diotallevi F, Radi G, Offidani A. Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption. Case Rep Dermatol. 2019 Sep 23;11:4-10. doi: 10.1159/000501992. eCollection 2019. PMID: 31662732; PMCID: PMC6816126.
Copy Download .nbib Format: NLM
Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines.

Pigment cell & melanoma research

Campagna R, Salvolini E, Pompei V, Pozzi V, Salvucci A, Molinelli E, Brisigotti V, Sartini D, Campanati A, Offidani A, Emanuelli M.
PMID: 34018676
Pigment Cell Melanoma Res. 2021 Nov;34(6):1039-1048. doi: 10.1111/pcmr.12993. Epub 2021 May 28.

Melanoma accounts for less than 5% of all cutaneous neoplasms but is responsible for the greater part of skin cancer-related deaths. Therefore, the identification of molecules that could serve as the therapeutic target is urgent. This study focused on...

Cite
Campagna R, Salvolini E, Pompei V, et al. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell Melanoma Res. 2021;34(6):1039-1048doi: 10.1111/pcmr.12993.
Campagna, R., Salvolini, E., Pompei, V., Pozzi, V., Salvucci, A., Molinelli, E., Brisigotti, V., Sartini, D., Campanati, A., Offidani, A., & Emanuelli, M. (2021). Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment cell & melanoma research, 34(6), 1039-1048. https://doi.org/10.1111/pcmr.12993
Campagna, Roberto, et al. "Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines." Pigment cell & melanoma research vol. 34,6 (2021): 1039-1048. doi: https://doi.org/10.1111/pcmr.12993
Campagna R, Salvolini E, Pompei V, Pozzi V, Salvucci A, Molinelli E, Brisigotti V, Sartini D, Campanati A, Offidani A, Emanuelli M. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell Melanoma Res. 2021 Nov;34(6):1039-1048. doi: 10.1111/pcmr.12993. Epub 2021 May 28. PMID: 34018676.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries